Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2026-05-19 07:30:05 ET · period of report 2026-05-18 · accession 0001193125-26-229656 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-19 07:30 | 2026-05-18 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +15.0K | 247.6K | +6% | +$31.2K |
| D | 2026-05-19 07:30 | 2026-05-18 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $0.00 | -15.0K | 12.7K | -54% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-18 | M | A | 15,000 | $2.08 | 247,588 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-05-18 | M | D | 15,000 | $0.00 | 12,653 | D | $2.08 · — to 2029-08-28 | 15,000 Common Stock | (F1) The shares underlying this stock option are fully vested and exercisable. |